These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 31629714)

  • 41. Low-level viraemia and virologic failure among people living with HIV who received maintenance therapy with co-formulated bictegravir, emtricitabine and tenofovir alafenamide versus dolutegravir-based regimens.
    Chen GJ; Sun HY; Chen LY; Hsieh SM; Sheng WH; Liu WD; Chuang YC; Huang YS; Lin KY; Wu PY; Chang HY; Luo YZ; Su YC; Liu WC; Chang SF; Chang SY; Hung CC
    Int J Antimicrob Agents; 2022 Sep; 60(3):106631. PubMed ID: 35787920
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bictegravir/emtricitabine/tenofovir alafenamide in paediatrics: Real-life experience from a French cohort (2019-2023).
    Frange P; Veber F; Burgard M; Blanche S; Avettand-Fenoel V
    HIV Med; 2024 Feb; 25(2):299-305. PubMed ID: 37807595
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of Emergent Dolutegravir Resistance Mutations in People Living with HIV: A Rapid Scoping Review.
    Chu C; Tao K; Kouamou V; Avalos A; Scott J; Grant PM; Rhee SY; McCluskey SM; Jordan MR; Morgan RL; Shafer RW
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543764
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial.
    Winston A; Post FA; DeJesus E; Podzamczer D; Di Perri G; Estrada V; Raffi F; Ruane P; Peyrani P; Crofoot G; Mallon PWG; Castelli F; Yan M; Cox S; Das M; Cheng A; Rhee MS
    Lancet HIV; 2018 Apr; 5(4):e162-e171. PubMed ID: 29475804
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load.
    Galizzi N; Galli L; Poli A; Gianotti N; Carini E; Bigoloni A; Tambussi G; Nozza S; Lazzarin A; Castagna A; Mancusi D; Termini R
    PLoS One; 2018; 13(2):e0191300. PubMed ID: 29451870
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy.
    Svärd J; Mugusi S; Mloka D; Neogi U; Meini G; Mugusi F; Incardona F; Zazzi M; Sönnerborg A
    PLoS One; 2017; 12(6):e0178942. PubMed ID: 28582463
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients.
    Ciccullo A; Baldin G; Capetti A; Rusconi S; Sterrantino G; d'Ettorre G; Colafigli M; Modica S; Lagi F; Giacomelli A; Cossu MV; Restelli S; De Luca A; Di Giambenedetto S
    Antivir Ther; 2019; 24(1):63-67. PubMed ID: 30277466
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Virological responses to lamivudine or emtricitabine when combined with tenofovir and a protease inhibitor in treatment-naïve HIV-1-infected patients in the Dutch AIDS Therapy Evaluation in the Netherlands (ATHENA) cohort.
    Rokx C; Gras L; van de Vijver D; Verbon A; Rijnders B;
    HIV Med; 2016 Sep; 17(8):571-80. PubMed ID: 26842457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Drug resistance and optimizing dolutegravir regimens for adolescents and young adults failing antiretroviral therapy.
    Kouamou V; Manasa J; Katzenstein D; McGregor AM; Ndhlovu CE; Makadzange AT
    AIDS; 2019 Sep; 33(11):1729-1737. PubMed ID: 31361272
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predicted antiviral activity of tenofovir versus abacavir in combination with a cytosine analogue and the integrase inhibitor dolutegravir in HIV-1-infected South African patients initiating or failing first-line ART.
    Derache A; Iwuji CC; Danaviah S; Giandhari J; Marcelin AG; Calvez V; de Oliveira T; Dabis F; Pillay D; Gupta RK
    J Antimicrob Chemother; 2019 Feb; 74(2):473-479. PubMed ID: 30380053
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients.
    Baldin G; Ciccullo A; Rusconi S; Capetti A; Sterrantino G; Colafigli M; d'Ettorre G; Giacometti A; Cossu MV; Borghetti A; Gennari W; Mussini C; Borghi V; Di Giambenedetto S
    Int J Antimicrob Agents; 2019 Dec; 54(6):728-734. PubMed ID: 31521809
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M; Parks DC; Ferrante S; Punekar Y
    AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
    [TBL] [Abstract][Full Text] [Related]  

  • 55. HIV-1 pretreatment and acquired antiretroviral drug resistance before tenofovir/ /lamivudine /dolutegravir (TLD) roll-out in Mozambique.
    Ismael N; Gemusse H; Mahumane I; Laurindo O; Magul C; Baxter C; Wilkinson E; Hofstra LM; Wagar N; Bila D; Mabunda N; da Silva J; Oliveira T; Raizes E; Preiser W; Manuel P; Ramos A; Vúbil A
    BMC Infect Dis; 2024 Jul; 24(1):748. PubMed ID: 39075381
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of nucleoside reverse transcriptase inhibitor backbone on the efficacy of first-line boosted highly active antiretroviral therapy based on protease inhibitors: meta-regression analysis of 12 clinical trials in 5168 patients.
    Hill A; Sawyer W
    HIV Med; 2009 Oct; 10(9):527-35. PubMed ID: 19785663
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Lamivudine-based maintenance antiretroviral therapies in patients living with HIV-1 with suppressed HIV RNA: derivation of a predictive score for virological failure.
    Borghetti A; Moschese D; Cingolani A; Baldin G; Speziale D; Ciccullo A; Lombardi F; Emiliozzi A; Belmonti S; Antinori A; Cauda R; Di Giambenedetto S
    HIV Med; 2019 Oct; 20(9):624-627. PubMed ID: 31240860
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Switching regimens in virologically suppressed HIV-1-infected patients: evidence base and rationale for integrase strand transfer inhibitor (INSTI)-containing regimens.
    Raffi F; Esser S; Nunnari G; Pérez-Valero I; Waters L
    HIV Med; 2016 Oct; 17 Suppl 5():3-16. PubMed ID: 27714978
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Switching to coformulated rilpivirine (RPV), emtricitabine (FTC) and tenofovir alafenamide from either RPV, FTC and tenofovir disoproxil fumarate (TDF) or efavirenz, FTC and TDF: 96-week results from two randomized clinical trials.
    Hagins D; Orkin C; Daar ES; Mills A; Brinson C; DeJesus E; Post FA; Morales-Ramirez J; Thompson M; Osiyemi O; Rashbaum B; Stellbrink HJ; Martorell C; Liu H; Liu YP; Porter D; Collins SE; SenGupta D; Das M
    HIV Med; 2018 Nov; 19(10):724-733. PubMed ID: 30101539
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.